Trials / Completed
CompletedNCT04172454
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
A Multicenter, Open-label,Phase 1b/2 Study for Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, open-label, phase 1b/2 study to evaluate the safety and efficacy of AK104, a PD-1 and CTLA-4 bispecific antibody, in selected advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AK104 | AK104, 6mg/kg, Q2W |
Timeline
- Start date
- 2019-12-20
- Primary completion
- 2021-06-17
- Completion
- 2022-09-23
- First posted
- 2019-11-21
- Last updated
- 2022-10-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04172454. Inclusion in this directory is not an endorsement.